<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773707</url>
  </required_header>
  <id_info>
    <org_study_id>Abatacept (IND)</org_study_id>
    <secondary_id>UC4DK106993</secondary_id>
    <secondary_id>UC4DK117009</secondary_id>
    <nct_id>NCT01773707</nct_id>
  </id_info>
  <brief_title>CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1</brief_title>
  <official_title>CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.

      All subjects will receive close monitoring for development of AGT or T1DM. Subjects will
      receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess
      the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.

      The primary objective is to determine whether intervention with Abatacept will prevent or
      delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of
      patients with T1DM.

      Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of
      C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic
      outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Purpose and Rationale:

      In this study, relatives who are confirmed to have two or more antibodies, not including
      mIAA, and normal glucose tolerance will be eligible for randomization to experimental
      treatment or placebo groups with the aim to determine whether experimental treatment will
      prevent or delay the occurrence of abnormal glucose tolerance and type 1 diabetes mellitus.
      Individuals with normal glucose tolerance are earlier in the disease process; that is, have
      less beta cell destruction than those with abnormal glucose tolerance or frank diabetes, yet
      will inevitably progress to clinical disease and essentially complete beta cell loss.
      Treatment at this early stage in a population who will inevitably progress to type 1 diabetes
      provides the greatest opportunity for a clinically important impact on disease prevention.
      With abnormal glucose tolerance rather than diabetes as the primary endpoint, study
      participants, regulators, funders, and investigators will be able to determine whether the
      therapy can alter disease progression.

      Therefore, the rationale for this study is that individuals with immunologic markers of T1DM
      and normal glucose tolerance will inevitably develop clinical T1DM. Prior to development of
      clinical T1DM they will progress from normal glucose tolerance to abnormal glucose tolerance;
      and abnormal glucose tolerance results in clinical T1DM within 5 years in almost 80% of
      subjects. They have a condition that differs from overt diabetes only in the duration of the
      autoimmune process that results in beta cell destruction. Intervention early in the course of
      disease may be more effective than intervention in those with abnormal glucose tolerance or
      clinical T1DM.

      Description of Treatment Groups

      Subjects will be randomized to receive either Abatacept or placebo infusions along with close
      monitoring for abnormal glucose tolerance or diabetes. The infusions will be conducted at
      approved TrialNet clinical sites with appropriate facilities. All blood and serum samples for
      the primary and secondary outcome determinations will be sent to the Core Laboratories for
      analysis. Clinical laboratory studies may be done at the local sites.

      Participants will be randomly assigned in a 1:1 ratio (within the two strata defined by age
      at enrollment: &lt;18 and 18 or older) to the following 2 groups:

        -  to receive Abatacept (intravenous infusion at 0, 2, and 4 weeks following randomization,
           and then every 28+/-7 days) thereafter for a total of 14 doses. Close monitoring for
           diabetes development through the duration of study.

        -  to receive placebo intravenous infusion at 0, 2, and 4 weeks following randomization and
           then every 28+/- 7 days thereafter for a total of 14 doses. Close monitoring for
           diabetes development through the duration of study.

      Treatment Assignment

      After participants sign the consent form, complete the screening visit(s), and meet all of
      the inclusion criteria and none of the exclusion criteria, participants will be randomized to
      receive either Abatacept and close monitoring or placebo with close monitoring.

      Participants will be randomized in equal allocations to each group. The randomization method
      will be stratified by TrialNet study site and whether the participant is less than 18 years
      of age or 18 years and older. This approach ensures that study site will not be a potential
      confounder. The TNCC will generate the randomization numbers and tables.

      Study Assessments

      During the course of the study, participants will frequently undergo assessments of their
      glucose tolerance status, insulin production, immunologic status, and overall health and
      well-being.

      Samples will be drawn for storage in the National Institute for Diabetes and Digestive and
      Kidney Disease (NIDDK) Repository and at TrialNet Laboratory Sites for future analysis
      related to T1DM.

      Study Duration

      The study has been designed to provide 80% power to detect a 40% risk reduction in the
      occurrence of abnormal glucose tolerance using a two-sided test at the 0.05 level after six
      years of study duration. A total of approximately 206 patients will be allocated in a 1:1
      ratio to the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance</measure>
    <time_frame>every six months for 5-6 years</time_frame>
    <description>Measured by Oral Glucose Tolerance Test (OGTT):
Abnormal Glucose Tolerance is primary endpoint and defined as:
Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L) and &lt; 126 mg/dL (7 mmol/L), or
2 hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L) and &lt; 200 (11.1 mmol/L), or
30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide response to Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>Every six months for 5-6 years</time_frame>
    <description>To Determine whether treatment with Abatacept is superior to placebo with respect to C-peptide response to oral glucose tolerance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Abnormal Glucose Tolerance</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>abatacept IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTLA4-Ig (Abatacept)</intervention_name>
    <description>Given as 30 minute IV infusion</description>
    <arm_group_label>abatacept IV infusion</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline given as 30 minute IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant in TrialNet Natural History/Pathway to Prevention Study and thus, a
             relative of a proband with T1DM.

          -  Between the ages of 1-45 years at the time of enrollment in TN01 and age ≥ 6 at time
             of randomization in this trial.

          -  Willing to provide Informed Consent or have a parent or legal guardian provide
             informed consent if the subject is &lt;18 years of age.

          -  Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of
             baseline (visit 0). If previous abnormal glucose tolerance, has had two consecutive
             OGTTs with normal glucose tolerance.

               1. Fasting plasma glucose &lt; 110 mg/dL (6.1 mmol/L), and

               2. 2 hour plasma glucose &lt;140 mg/dL (7.8 mmol/L), and

               3. 30, 60, or 90 minute value on OGTT&lt; 200mg/dL (11.1 mmol/L)

          -  At least two diabetes-related autoantibodies confirmed to be present on two occasions,
             not including mIAA. Confirmation of 2 positive autoantibodies must occur within the
             six months prior to randomization, but the confirmation does not have to involve the
             same 2 autoantibodies.

          -  Weight ≥ 20 kg at Baseline Visit.

          -  If a female participant with reproductive potential, willing to avoid pregnancy and
             undergo pregnancy testing prior to each infusion.

          -  At least three months from date of last live immunization.

          -  Willing to forgo live vaccines while receiving treatment on study and for three months
             following last study drug administration.

        Exclusion Criteria:

          -  Abnormal Glucose Tolerance or Diabetes

               1. Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L), or

               2. 2 hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or

               3. 30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)

          -  Insulin autoantibodies (mIAA).

          -  Are immunodeficient or have clinically significant chronic lymphopenia.

          -  Have an active infection at time of randomization.

          -  Have a positive PPD test result or history of previously treated TB, or positive
             interferon-gamma release assay (IGRA) test.

          -  Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of
             the last study drug administration.

          -  Use of medications known to influence glucose tolerance.

          -  Require use of other immunosuppressive agents.

          -  Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B
             core antibody or surface antigen), or Hepatitis C infection.

          -  Have serological evidence of current CMV infection.

          -  Have evidence of active EBV infection.

          -  Have any complicating medical issues or abnormal clinical laboratory results that
             interfere with study conduct or cause increased risk. These include pre-existing
             cardiac disease, COPD, neurological, or blood count abnormalities (such as
             lymphopenia, leukopenia, or thrombocytopenia).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla J Greenbaum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Type 1 Diabetes TrialNet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa E Rafkin, MS</last_name>
    <phone>305-243-6146</phone>
    <email>lrafkin@miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan O'Donnell, MS</last_name>
    <email>ryan.o'donnell@epi.usf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ng</last_name>
      <phone>415-514-3730</phone>
      <email>NgDavid@peds.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Breen, RN, CDE</last_name>
      <phone>(415) 502-8640</phone>
      <email>breenk@peds.ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trudy Esrey, RD</last_name>
      <phone>650-498-4450</phone>
      <email>tesrey@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes, University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Weiner, RN</last_name>
      <phone>303-315-0266</phone>
      <email>Laurie.Weiner@uchsc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Medical School</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurie Feldman, RN</last_name>
      <phone>203-737-2760</phone>
      <email>laurie.feldman@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Cook, RN</last_name>
      <phone>352-294-5759</phone>
      <email>cookrb@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Desmond A. Schatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson, RN</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Marks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Gannon</last_name>
      <phone>773-702-3853</phone>
      <email>ggannon@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Louis Philipson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University-Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nicholson</last_name>
      <email>malnicho@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Linda DiMeglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>57931</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Smith, RN</last_name>
      <phone>612-624-6682</phone>
      <email>smit5759@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Antoinette Moran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Greenberg, MPH</last_name>
      <phone>212-851-5425</phone>
      <email>emg25@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Golan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Riley, RN</last_name>
      <phone>412-692-5210</phone>
      <email>karen.riley@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Riley, RN</last_name>
      <phone>412-692-5210</phone>
      <email>karen.rileyy@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith Brendle</last_name>
      <phone>615-936-8638</phone>
      <email>faith.brendle@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>William Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Raskin, M.D.</last_name>
      <phone>214-648-4844</phone>
      <email>philip.raskin@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lourdes Pruneda, RN</last_name>
      <phone>(214) 648-4717</phone>
      <email>Maria.pruneda@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Philip Raskin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Pena</last_name>
      <phone>832-822-3380</phone>
      <email>sypena@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Maria Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute at Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marli McCulloch-Olson</last_name>
      <phone>800-888-4187</phone>
      <email>marli@vmresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>MSG-1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Eisel, RN</last_name>
      <phone>416-813-8159</phone>
      <email>lesley.eisel@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Wherrett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetestrialnet.org</url>
    <description>TrialNet</description>
  </link>
  <reference>
    <citation>Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.</citation>
    <PMID>21719096</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention of type 1 diabetes</keyword>
  <keyword>prevention of abnormal glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

